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doi:10.1016/j.ejvs.2009.03.027Abstract Objectives: Topical wound oxygen (TWO2) may help wound healing in the manage-
ment of refractory venous ulcers (RVU). The aim of this study was to measure the effect of
TWO2 on wound healing using the primary end-point of the proportion of ulcers healed at
12 weeks. Secondary end-points were time to full healing, percentage of reduction in ulcer
size, pain reduction, recurrence rates and Quality-Adjusted Time Spent Without Symptoms
of disease and Toxicity of Treatment (Q-TWiST).
Design: A parallel observational comparative study.
Methods: Patients with CEAP C6,s RVU, assessed by duplex ultrasonography, were managed
with either TWO2 (nZ 46) or conventional compression dressings (CCD) (nZ 37) for 12 weeks
or till full healing. Patients were followed up at 3 monthly intervals.
Results: At 12 weeks, 80% of TWO2 managed ulcers were completely healed, compared to 35%
of CCD ulcers (p< 0.0001). Median time to full healing was 45 days in TWO2 patients and 182
days in CCD patients (p < 0.0001). The pain score threshold in TWO2 managed patients
improved from 8 to 3 by 13 days. After 12-month follow-up, 5 of the 13 healed CCD ulcersFRCS, EBQS-VASC, Consultant Vascular & Endovascular Surgery, Western Vascular Institute, Depart-
urgery, University College Hospital Galway (UCHG), Newcastle Road, Galway, Ireland. Tel.: þ353
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126 W. Tawfick, S. Sultanshowed signs of recurrence compared to none of the 37 TWO2 healed ulcers. TWO2 patients
experienced a significantly improved Q-TWiST.
Conclusion: TWO2 reduces recurrence rates, alleviates pain and improves the Q-TWiST. We
believe it is a valuable tool in the armamentarium of management of RVU.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Refractory venous leg ulceration is a common source of
morbidity1,2 and reduced quality of life,3 especially in the
elderly population.4,5 The prevalence of venous ulcers has
been estimated at 0.3% within the UK population,6,7 with
comparable rates in other countries.5,8e10 There is a prob-
able underestimation of the true extent due to under-
reporting.2
Venous ulcers are characterized by a cyclical pattern of
healing and recurrence,11 with recurrence rates up to 70%
at one year.12e16
Venous ulceration places a huge burden on the health-
care system.17 The cost of managing venous ulcers amasses
to £400 million sterling per year in the UK.18 It causes
a considerable amount of morbidity amongst patients, with
work incapacity, social exclusion and lack of self esteem.3
Conventional compression dressings (CCD) are now
widely recognised as the main treatment for venous leg
ulcers,19e22 with the addition of surgical correction of
superficial venous reflux to reduce recurrence rates.23,24
However, the socio-economic implications of management
of RVU, combined with high recurrence rates have stimu-
lated the development of innovative therapies, as Topical
Wound Oxygen (TWO2) therapy.
The application of positive pressure oxygen to manage
open wounds has been studied extensively for decades,
demonstrating promising clinical results.25e33 The tradi-
tional limitations of a full body hyperbaric chamber have
been overcome by an approach that allows the application
of topical wound pure oxygen at an appropriate cycled
pressure to only the specific wound site. This maximizes the
beneficial wound healing effects and minimizes the nega-
tive systemic side effects.34
The intermittent cycled pressure, under which the TWO2
is delivered, stimulates circulation, reduces oedema and
provides a sealed humidified environment essential for
healing.35 TWO2 promotes epithelialisation and capillary
neoangiogenesis.34,35 This leads to higher tensile strength
collagen being formed during wound healing, which reduces
scarring and the risk of recurrence.36e39
Objectives
This parallel group observational comparative study was
aimed at examining the safety and efficacy of TWO2 in
managing refractory venousulcers (RVU).Weaimtocompare
the outcome of using TWO2 to that of CCD in chronic RVU.
Primary end-points
The primary end-point study is the proportion of ulcers
healed at 12 weeks.Secondary end-points
Secondary end-points are time taken for full healing,
percentage of reduction in the ulcer size at 12 weeks, MRSA
elimination, pain reduction, recurrence rates and Quality-
Adjusted Time Spent Without Symptoms of disease and
Toxicity of treatment (Q-TWiST).
Methods
Ethical approval was obtained from the local research
ethics committee. Patients with chronic refractory non-
healing venous ulcers, with an ulcer of more than two years
duration, were recruited from the vascular unit in a tertiary
referral centre. All patients had to have shown no sign of
improvement of the ulcer over the past year, despite
adequate compliance with appropriate treatment,
provided by community based leg ulcer clinics (Table 1).
All patients were managed on an intention to treat
basis. They were given the choice to either be managed
using CCD or TWO2. Patients were fully briefed on both
therapies and treatment was discussed with their primary
care physician and local tissue viability nurse. Allocation to
treatment was based on patient’s choice. All patients
signed an informed consent prior to commencement of
therapy.
Inclusion criteria:
 Written informed consent
 18 years of age
 Venous ulcer, with normal ankleebrachial index (ABI)
0.9 and digital pressures 0.7
 Duration of ulcer of more than two years
 No improvement over the past year.
Exclusion criteria:
 Bed ridden patients
 Ischaemic ulcers
 Diabetic ulcers
 Osteomyelitis
 Presence of gangrene
 Deep venous thrombosis
Patients underwent a venous duplex scan and a full
CEAP40,41 assessment (Table 1). ABIs and big toe digital
pressures were measured. Punch biopsies were taken from
all patients.
Patients were assessed regarding the anatomical loca-
tion of the ulcer, duration of presence of the ulcer, signs of
infection, slough and cellulitis. All vascular risk factors
were noted.
The leg ulcer was swabbed and a sample taken for
culture and sensitivity.
Table 1 Demographics. There was no significant difference between both groups in vascular related risk factors, the CEAP
class of the patient, or the treatment patients had received prior to the study.
Demographics TWO2 CCD p value
Number of ulcers 46 37
Age (mean/range) 66 yrs (rangeZ 49e83 yrs) 65 yrs (rangeZ 44e87 yrs) pZ 0.860
Gender (M:F) 29:17 24:13 pZ 0.524a
Diabetes mellitus nZ 15 nZ 11 pZ 0.484a
Smoking nZ 4 nZ 1 pZ 0.255a
Hypertension nZ 22 nZ 15 pZ 0.330a
MRSA positive nZ 19 nZ 17 pZ 0.251a
Patient referred for
primary amputation
nZ 3 nZ 0 pZ 0.165a
CEAP classb
C6,s nZ 46 nZ 37
Ep nZ 33 nZ 27 pZ 0.423
a
Es nZ 13 nZ 10 pZ 0.396
a
As nZ 10 nZ 10 pZ 0.531
a
Ap nZ 7 nZ 4 pZ 0.347
a
As,p nZ 29 nZ 23 pZ 0.520
a
Pr nZ 33 nZ 27 pZ 0.423
a
Po nZ 2 nZ 2 pZ 0.325
a
Pr,o nZ 11 nZ 8 pZ 0.372
a
Previous treatment
SFJ ligation & division
(perforator avulsion)
nZ 5 nZ 3 pZ 0.275a
SFJ ligation, division & LSV stripping
(perforator avulsion)
nZ 19 nZ 17 pZ 0.251a
SPJ ligation & division
(perforator avulsion)
nZ 7 nZ 7 pZ 0.433a
Multilayer compression dressings nZ 34 nZ 21 pZ 0.214a
Local dressingþ Elastic stocking nZ 8 nZ 14 pZ 0.564a
Local dressingþ no compression nZ 4 nZ 2 pZ 0.207a
(SFJZ Sapheno-Femoral junction, LSVZ Long Saphenous Vein, SPJZ Sapheno-Popliteal junction).
a p values are Chi-Square.
b Basic CEAP classification.40
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on a scale from 1 to 10 using the pain numerical rating
scale, prior to therapy and repeated every 3 days.
Ulcers were cleaned, debrided, digitally photographed
and measured using a Visitrak system (Smith & Nephew Ltd,
Hull, UK), to determine the surface area and maximum
length and width of the ulcer.
Patients receiving CCD were managed in an outpatient
leg ulcer clinic, using Profore> multilayer compression
bandage system with underlying non-adherent Profore>
Wound Contact Layer (WCL) dressings (Profore> by Smith &
Nephew Ltd, Hull, UK). Dressings were applied by a tissue
viability nurse, supervised by the treating physician.
Dressings were changed, depending on the amount of
exudate, from one to three times per week, after cleaning,
debriding and re-measuring the wound.
TWO2 patients were managed in an inpatient setup, as
oxygen was delivered from piped oxygen wall outlets.
During treatment sessions, patients were seated, with the
affected limb extended and placed in the AOTI Hyper-Box
(AOTI Ltd, Galway, Ireland) for 180 min twice daily under
pressure of 50 mbar (Fig. 1). Oxygen was supplied at10 l/min with continuous humidification. Between sessions,
the limb was left exposed, with no dressings. Patients were
allowed to leave the ward or hospital between treatment
sessions, if they desired, during which the ulcer was
temporarily covered with a non-adherent WCL dressing and
gauze bandage, until they returned. No compression was
applied. Wounds were cleaned, debrided and re-measured
twice per week.42,43
Treatment was continued until full ulcer healing or for
12 weeks, whichever sooner. When full healing was ach-
ieved, patients from both treatment arms were
commenced on class II elastic stockings. Patients who did
not achieve full ulcer healing by 12 weeks, in either
treatment arm, were considered failures of treatment.
They were managed with CCD and continued to be seen on
a weekly basis. Patients were followed up at three monthly
intervals following cessation of therapy.
End-points were assessed at 12 weeks, apart from the
time to full ulcer healing which continued to be assessed
beyond the 12-week point. Recurrence rates and Q-TWiST
were assessed throughout the treatment and follow-up
period.
Figure 1 Limb in AOTI Hyper-Box. Patient with a medial
maleolar ulcer during a TWO2 treatment session, with the limb
placed inside the AOTI Hyper-Box. Oxygen and pressure seal
are maintained by the rubber cuff, placed below the knee.
Table 2 Characteristics of the leg ulcers. There was no
statistically significant difference between both treatment
groups, regarding the anatomical location of the ulcer, the
size of the ulcer, or the duration the patient had the ulcer.
Anatomical distribution TWO2 CCD p value
Medial maleolus nZ 18 nZ 14 pZ 0.543a
Lateral maleolus nZ 12 nZ 11 pZ 0.450a
Calf nZ 8 nZ 6 pZ 0.563a
Shin nZ 8 nZ 6 pZ 0.563a
Ulcer surface area
5 cm2 nZ 6 nZ 6 pZ 0.459b
6e10 cm2 nZ 7 nZ 5 pZ 0.541b
11e20 cm2 nZ 17 nZ 12 pZ 0.423b
21e40 cm2 nZ 7 nZ 7 pZ 0.437b
41 cm2 nZ 9 nZ 7 pZ 0.584b
Duration of the ulcer
2e3 years nZ 10 nZ 9 pZ 0.492b
4e5 years nZ 16 nZ 10 pZ 0.303b
6e10 years nZ 12 nZ 12 pZ 0.347b
11e20 years nZ 6 nZ 5 pZ 0.600b
Over 20 years nZ 2 nZ 1 pZ 0.582b
a p values are Chi-Square.
b p values are ManneWhitney U.
128 W. Tawfick, S. SultanSurvival time was divided into three periods;
Toxicity (TOX): time spent with toxicity of disease or
severe adverse events prior to disease progression.
TWiST: time spent without symptoms of disease
progression or toxicity of treatment.
Progression (PROG): Time spent with progression of
disease. Progression of disease was defined as ulcer
recurrence in fully healed ulcers, or increase in ulcer
size in ulcers that had not fully healed.
The mean time spent in each of the three periods was
determined separately for each treatment group, using the
KaplaneMeier method.
Mean Q-TWiST for each treatment arm was calculated
as44e46:
Q-TWiSTZðmTOX  TOXÞ þ TWiSTþ ðmPROG  PROGÞ
TOX, TWiST and PROG represented the mean health state
duration from KaplaneMeier analysis; mTOX and mPROG signify
the utility coefficients for TOX and PROG, respectively.
TWiST was considered to have utility of 1, indicating the
best possible quality of life for a patient with RVU.
mTOX and mPROG were weighted using a range of utility
scores, to reflect quality of time in each health state,
relative to TWiST. Sensitivity analyses were conducted by
varying the assigned utilities for TOX and PROG in 0.25
increments across the full range of possible utility weights
from 0 (representing poorest health) to 1.
Statistical analysis
Data were collected and analysed using SPSS 14 software
(SPSS Inc, Chicago, Illinois). Continuous variables were
compared with the independent sample t test. Categoric
proportions were compared using the Chi-Square test.
ManneWhitney U test was performed to compare unpaired,
non-parametric data. Time to healing & Q-TWiST were
assessed using KaplaneMeier with Log-rank comparison.Results
46 limbs with 46 ulcers were managed using TWO2 therapy.
37 limbs with 37 ulcers were managed using CCD. 63% of the
TWO2 patients were men (nZ 29). 65% of the CCD patients
were men (nZ 24, pZ 0.524, Table 1).
Risk factors were similar in both treatment groups (Table 1).
There was no significant difference between both groups in
the anatomical distribution of ulcers, size of the ulcers or
the duration the patient had the ulcer (Table 2).
19/46 ulcers were MRSA positive in the TWO2 group,
while 17/37 were MRSA positive in the CCD group
(pZ 0.251) (Table 1).
Using the CEAP classification all patients were classified
as C6,s.
40,41
Using the Venous Clinical Severity Score,47e49 the mean
score in TWO2 patients was 25, and was 23 in CCD patients.
Following commencement of TWO2 therapy, there was
an initial latent phase up to five days, where no reduction in
surface area was seen. This was followed by a period of
rapid improvement, where ulcers reached 70% reduction in
surface area. This was followed by a plateau where healing
slowed down until either near healing or full healing
(Fig. 2).
89% of the TWO2 managed ulcers showed a reduction in
surface area by 3weeks of treatment (nZ 41/46),
compared to 68% of CCD ulcers (nZ 25/37, pZ 0.016).
The proportion of ulcers completely healed by 12 weeks
was 80% in the TWO2 group (nZ 37/46) in contrast to 35% of
the CCD group (nZ 13/37, p< 0.0001).
The mean reduction in ulcer surface area at 12 weeks
was 96% in the TWO2 therapy group, compared to 61% in the
CCD group.
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Figure 2 Mean reduction in surface area. There was an
initial latent phase up to 5 days, followed by rapid improve-
ment, where ulcers reached 70% reduction in surface area. This
was followed by a plateau of slow improvement.
TWO2 Vs CCD in Managing Refractory Venous Ulcers 129The median time to full ulcer closure was 45 days in the
TWO2 group (95% CI: 39e51), compared to 182 days in the
Profore> group (95% CI: 162e203, p< 0.0001) (Fig. 3).
Within the TWO2 group, the duration the patient had the
ulcer and the size of the ulcer, did not affect the healing
time. TWO2 managed ulcers had a significantly shorter
healing time, compared to CCD ulcers, regardless of the
duration of ulcer (p< 0.0001) or the size of the ulcer
(p< 0.0001).
Three of the TWO2 patients were referred to our service
for primary amputation following failure of other treatment
modalities, including skin grafting. These three ulcers
healed completely and none of these patients required
amputation.
Three of the TWO2 ulcers showed no signs of healing at
4 weeks. One patient had an ulcer exposing tendons and
bone. Histology proved that the other two patients have
underlying basal cell carcinoma (nZ 1) and squamous cell
carcinoma (nZ 1).
32/46 of the TWO2 treated ulcers showed a reverse
gradient of healing, where healing commenced from the
centre of the ulcer and expanded towards the periphery
(Fig. 4). Using the pain numerical rating scale, the painFigure 3 Time to full healing. KaplaneMeier curve showing
time to full ulcer healing. TWO2 managed ulcers had a signifi-
cantly shorter median time to full healing (45 days) compared
to 182 days in CCD managed ulcers (p< 0.0001).score threshold in the TWO2 managed patients improved
from 8 to 3 by 13 days.
9 of the 19 MRSA positive ulcers in the TWO2 therapy
group were MRSA negative after 5 weeks of treatment
regardless of closure of the ulcer, compared to none of the
17 MRSA positive ulcers in the CCD group (pZ 0.007).
No local or systemic complications were encountered in
either treatment group.
Patients were followed up for a mean of 12 months.
During that period, 2 TWO2 patients underwent varicose
vein surgery, while 5 patients (2 TWO2 and 3 CCD) under-
went redo-varicose vein surgery.
During follow-up, none of the 37 fully healed TWO2
managed ulcers showed signs of recurrence. In comparison,
5 of the 13 fully healed CCD managed ulcers showed signs of
recurrence. Furthermore, 2 CCD managed ulcers that had
not completely healed, showed signs of deterioration and
increase in surface area.
TWO2 patients had a significantly shorter mean TOX (1.5
months), in comparison to CCD patients (6 months,
p< 0.001). TWO2 patients had a significantly longer mean
TWiST (12.5 months), opposed to 4.5 months in CCD
patients (p< 0.001).
TWO2 patients had no PROG, in contrast to a mean PROG
of 3 months for CCD patients (p< 0.0001).
TWO2 patients experienced an overall improved Q-TWiST
when assigned any utility coefficient, across the full range
of possible utility weights. When the utility coefficient
assigned was 0.5 the Q-TWiST for TWO2 patients was 13.625
compared to 27 in the CCD group (p< 0.0001, Table 3).
Discussion
Compression therapy within the setup of a leg ulcer clinic is
widely recognised as the main modality for managing
venous leg ulcers.19e22 High recurrence rates and the socio-
economic burden of RVU, have motivated the development
of alternative therapies as TWO2 therapy.
The first publication on the use of TWO2 was by Fischer
in 1969.25 Fischer noted that lesions became aseptic and
enhanced granulation was witnessed two days after TWO2.
These findings are similar to our own results. In our study,Figure 4 Reverse gradient of healing. Healing starts at the
centre of the ulcer & then spreads outwards.
Table 3 Quality Time Spent Without Symptoms of Disease
and Toxicity of Treatment (Q-TWiST) was significantly
improved in TWO2 patients.
Time period TWO2 CCD p value
TOX 1.5 months 6 months p< 0.0001
TWiST 12.5 months 4.5 months p< 0.0001
PROG 0 3 months p< 0.0001
Q-TWiST 13.625 27 p< 0.0001
130 W. Tawfick, S. Sultanhowever, no improvement was witnessed within the first
four to five days of TWO2. This discrepancy in timing of
clinical improvement could be attributed to the difference
in treatment regimes. While Fischer used a constant pres-
sure of 22 mmHg, the AOTI Hyper-Box used in our study
cycled the pressure between atmospheric pressure and
50 mbar.
A series of feasibility studies and randomised controlled
studies, assessed a mixed aetiology of ulcers and none were
dedicated to assess the effect of TWO2 on RVU.
25e33 We
believe our study to be the first study on the use of TWO2 in
RVU.42,43
In a prospective randomised study by Heng et al, red
granulation tissue was present one week after TWO2.
32
Heng noted absence of clinical scarring and most ulcers
healed within 2e16 weeks. This mimics our findings where
healthy granulation tissue was witnessed in the ulcers
following four to five days of TWO2.
In both our own study and the Heng study,32 positive
effects could be found, whereas in a study by Leslie et al.
no significant effects could be detected.33 The treatment
schedule in the Leslie study was short, which could have
had an impact on the overall results. Two daily 90-min
sessions were applied for 7e14 days, compared to 4-h
a day, 4 days a week over 4 weeks in the ‘‘positive’’ Heng
study32 and 3-h bi-daily, 7 days a week in our study.
In our study, treatment was commenced at 90-min
sessions once daily, in the first 5 cases where TWO2 was
used. These patients were excluded from this study analysis
and are not a subset of the 46 patients managed with TWO2.
We noted minimal response within the first 10 days of
treatment. Through close monitoring and adjusting our
protocol, treatment sessions were increased gradually until
reaching 180-min sessions bi-daily, where an adequate
response was witnessed and no safety concerns were
observed.42,43
During TWO2 therapy sessions, patients endured limb
elevation. These patients had their ulcers for a minimum of
2 years(up to 43years), and had already shown no signs of
improvement over the past year, despite adequate
compliance with treatment. While accepting that this may
have assisted in ulcer healing, it would be futile to attribute
the improved outcome to limb elevation alone.
In our study, only 35% of ulcers managed with CCD fully
healed. Whilst accepting that this is a lower rate than most
published studies on this treatment, yet the refractory
nature of these ulcers, has to be taken into consideration.
Fischer et al.,28 showed reduced rates of infection with
TWO2. This depicts our findings, where 9 of the 19 MRSA
positive ulcers in the TWO2 group were rendered MRSA
negative after 5 weeks of treatment.Cronje stated that if topical oxygen could increase
wound oxygen levels, it would create a reverse gradient,
with higher values in the wound than in the periphery.50 In
our study 69.5% (nZ 32/46) of the TWO2 treated ulcers
showed reverse gradient of healing. All these ulcers further
continued to fully heal with minimal scarring and no
recurrence. This could be attributed to topical absorption
of oxygen, leading to formation of higher tensile strength
collagen.36e38
Despite the fact that the mean Venous Clinical Severity
Score47e49 was higher in TWO2 patients, yet an improved
outcome was witnessed compared to CCD patients.
Ulcers that showed no signs of healing in the TWO2
group, proved to have an underlying cause. One patient had
an ulcer exposing tendons and bone. The other two ulcers
had underlying malignancy. Since this finding, evidence of
mitotic activity was added as an exclusion criterion.
TWO2 patients had a significantly improved Q-TWiST
compared to CCD patients, denoting an improved outcome
(p< 0.0001). TWO2 patients had a significantly shorter
mean period of time with TOX (p< 0.0001). This is attrib-
uted to the significantly shorter time to full ulcer closure
and higher percentage of ulcers that achieved full healing.
TWO2 patients had a significantly longer mean TWiST
(p< 0.0001). TWO2 managed patients did not experience
any complications from their therapy. There was no
recurrence of the ulcers or pain witnessed in the TWO2
patients.
TWO2 patients had no time with PROG, compared to
a mean period of 3 months of PROG in CCD patients
(p< 0.0001). In the TWO2 group, once healing of the ulcer
was achieved, these patients continued to maintain an ulcer
free course over a mean period of 12 months of follow-up,
with no recurrence of symptoms or progress of disease.
Conclusion
TWO2 is safe and effective in RVU management. It has
a superior outcome to CCD, through achieving a shorter
healing time, alleviating pain, reducing recurrence rates
and improving the Q-TWiST. We believe that TWO2 is
a valuable tool in the armamentarium of management of
patients with RVU, without the risks of full body hyperbaric
chambers.
Following these initial observational findings, a rando-
mised controlled trial is currently underway to further
assess the benefits of TWO2 therapy.
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